Diametric Capital LP Makes New $203,000 Investment in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Diametric Capital LP acquired a new stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,600 shares of the company’s stock, valued at approximately $203,000.

Other hedge funds also recently modified their holdings of the company. CoreFirst Bank & Trust bought a new position in GE HealthCare Technologies in the 4th quarter valued at about $25,000. Runnymede Capital Advisors Inc. bought a new position in shares of GE HealthCare Technologies during the fourth quarter worth approximately $28,000. Continuum Advisory LLC lifted its holdings in GE HealthCare Technologies by 101.8% during the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after purchasing an additional 168 shares during the last quarter. Bank of Jackson Hole Trust acquired a new stake in GE HealthCare Technologies during the 4th quarter worth approximately $32,000. Finally, OFI Invest Asset Management acquired a new position in GE HealthCare Technologies in the 4th quarter valued at $34,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Citigroup lifted their target price on GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. The Goldman Sachs Group raised shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $85.00 to $100.00 in a report on Tuesday, March 11th. Wells Fargo & Company raised their target price on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Finally, Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and lifted their price target for the company from $95.00 to $103.00 in a research report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, GE HealthCare Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $97.73.

GE HealthCare Technologies Trading Down 0.3 %

Shares of GEHC stock opened at $79.36 on Thursday. GE HealthCare Technologies Inc. has a fifty-two week low of $74.51 and a fifty-two week high of $94.80. The stock’s fifty day moving average price is $86.30 and its two-hundred day moving average price is $85.71. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.83 and a current ratio of 1.04. The company has a market cap of $36.29 billion, a PE ratio of 18.33, a P/E/G ratio of 3.19 and a beta of 1.13.

GE HealthCare Technologies (NASDAQ:GEHC) last released its earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.19. The firm had revenue of $5.32 billion for the quarter, compared to analysts’ expectations of $5.33 billion. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. Equities analysts predict that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

GE HealthCare Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Friday, April 25th will be paid a $0.035 dividend. This represents a $0.14 annualized dividend and a yield of 0.18%. The ex-dividend date is Friday, April 25th. GE HealthCare Technologies’s payout ratio is 3.23%.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.